PROFILPELAJAR.COM

Setidegrasib

Setidegrasib
Clinical data
Other namesASP-3082
Identifiers
  • (2S,4R)-1-[(2S)-2-[4-[4-[[6-cyclopropyl-4-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptan-2-yl]-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-(oxan-4-yloxy)quinazolin-8-yl]oxymethyl]phenyl]triazol-1-yl]-3-methylbutanoyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
PDB ligand
Chemical and physical data
FormulaC60H65FN12O7S
Molar mass1117.32 g·mol−1
3D model (JSmol)
  • CC1=C(C=C2C(=C1C3=C(C=C4C(=C3OCC5=CC=C(C=C5)C6=CN(N=N6)[C@@H](C(C)C)C(=O)N7C[C@@H](C[C@H]7C(=O)N[C@@H](CO)C8=CC=C(C=C8)C9=C(N=CS9)C)O)N=C(N=C4N1C[C@@H]3C[C@H]1CN3)OC1CCOCC1)C1CC1)C=NN2)F
  • InChI=InChI=1S/C60H65FN12O7S/c1-31(2)54(59(77)72-26-41(75)20-50(72)58(76)65-49(28-74)37-11-13-38(14-12-37)56-33(4)63-30-81-56)73-27-48(69-70-73)36-7-5-34(6-8-36)29-79-55-52(51-32(3)46(61)22-47-45(51)24-64-68-47)43(35-9-10-35)21-44-53(55)66-60(80-42-15-17-78-18-16-42)67-57(44)71-25-39-19-40(71)23-62-39/h5-8,11-14,21-22,24,27,30-31,35,39-42,49-50,54,62,74-75H,9-10,15-20,23,25-26,28-29H2,1-4H3,(H,64,68)(H,65,76)/t39-,40-,41+,49-,50-,54-/m0/s1
  • Key:XXWMEQMGQNHRAF-WFJRNIGCSA-N

Setidegrasib is an investigational new drug that is being evaluated by Astellas Pharma for the treatment of solid tumors.[1] It is an PROTACs degrader of the KRAS protein harboring a G12D mutation.[1][2][3]

Clinical trials

Setidegrasib in combination with either FOLFIRINOX or NALIRIFOX chemotherapy is currently in phase 3 clinical trials for the treatment of pancreatic cancer.[4]

References

  1. ^ a b "Setidegrasib - Astellas Pharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Zhang YB, Fu JW, Liu Y, Wu RL, Liang YT, Zhang WH, et al. (July 2026). "Targeted protein degradation: bridging chemical biology and clinical translation". Acta Pharmacologica Sinica. doi:10.1038/s41401-026-01861-2. PMID 42414544.
  3. ^ Yoshinari T, Nagashima T, Ishioka H, Inamura K, Nishizono Y, Tasaki M, et al. (August 2025). "Discovery of KRAS(G12D) selective degrader ASP3082". Nature Communications Chemistry. 8 (1) 254. Bibcode:2025CmChe...8..254Y. doi:10.1038/s42004-025-01662-4. PMC 12375097. PMID 40849515.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  4. ^ Clinical trial number NCT07409272 for "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given with either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People with Pancreatic Cancer" at ClinicalTrials.gov
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.